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Abstract
The prognosis for patients with oral squamous cell carcinoma remains poor in spite of advances in therapy of
many other malignancies. Early diagnosis and treatment remains the key to improved patient survival. Because the
scalpel biopsy for diagnosis is invasive and has potential morbidity, it is reserved for evaluating highly suspicious
lesions and not for the majority of oral lesions which are clinically not suspicious. Furthermore, scalpel biopsy has
significant interobserver and intraobserver variability in the histologic diagnosis of dysplasia. There is an urgent
need to devise critical diagnostic tools for early detection of oral dysplasia and malignancy that are practical,
noninvasive and can be easily performed in an out-patient set-up. Diagnostic tests for early detection include
brush biopsy, toluidine blue staining, autofluorescence, salivary proteomics, DNA analysis, biomarkers and
spectroscopy. This state of the art review critically examines these tests and assesses their value in identifying oral
squamous cell carcinoma and its precursor lesions.
Keywords: Oral Cancer, Diagnosis, Brush Biopsy, DNA, Saliva, Biomarkers, Spectroscopy
Introduction
In a recent report from the American Cancer Society, it
was estimated that 36,540 new cases of oral cavity and
pharyngeal malignancies are likely to be diagnosed in
the United States during 2010, and 7,880 patients will
die of the disease. In developed countries like the United
States, the five year survival was 63% between 1999-2005
- an increase from 53% during the time period from
1975-77; this difference was found to be statistically sig-
nificant[1]. The improved survival rates may be partially
explained by the increasing use of newer diagnostic
modalities that detect the disease in its precursor stage
and/or use of newer chemotherapeutic options.
Approaches to Early Detection of Dysplasia and Oral
Cancer
There are two approaches in the early detection of oral
dysplasia and cancer: 1) oral cancer screening programs
that identify asymptomatic patients with suspicious
lesions and 2) employing specific diagnostic tools to
identify dysplasia and early oral cancers in asymptomatic
patients with an oral abnormality. The benefits and lim-
itations of these approaches will be addressed in this
review.
Oral Cancer Screening
Screening for oral cancer implies searching for oral pre-
cancerous and cancerous lesions, typically before symp-
toms occur. A number of established cancer screening
programs for a variety of malignancies have been shown
to significantly reduce patient morbidity and mortality -
including the Pap test for cervical cancer and mammo-
graphy for breast cancer. However, several publications
have demonstrated that oral cancer screening has lim-
ited value as a method for detecting precancerous or
early cancerous lesions. In the only randomized con-
trolled oral cancer screening trial conducted in India
and involving over 130,000 individuals, the authors con-
cluded that visual examination was useful as a method
of screening for oral cancer only in high risk cases like
chronic smokers or alcoholics [2].
Oral cancer screening is fraught with problems includ-
ing the fact that approximately 5-15% of the general
population may have an oral mucosal lesion. While the
majority of these lesions are benign, clinical inspection
alone cannot differentiate which lesions are potentially
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precancerous and cancerous and which ones are benign.
The classic clinical presentation of a premalignant lesion
or malignancy includes a red spot, white spot or persis-
tent ulcer. However, only a small percentage of these
types of lesions are cancerous and an oral examination
unfortunately cannot discriminate between lesions that
are potentially dangerous from lesions that are benign.
A Cochrane review on this subject failed to find any evi-
dence to confirm or refute the usefulness of screening
for oral malignancies [3].
Early Diagnosis
Early detection of oral cancer is one of the most effi-
cient ways to reduce the high mortality from this dis-
ease. Early detection can minimize the morbidity of the
disease and its treatment, which is associated with a
severe loss of function, disfigurement, depression and
poor quality of life.
However, based upon the National Cancer Institute’s
SEER program, which collects data on oral cancer, there
has been little or no change in the past twenty years in
the detection of oral cancers at early stages [4]. Unfortu-
nately, most patients are diagnosed with advanced stage
disease.
Early detection therefore necessitates raising awareness
in the general public and improving access to oral
health services for all segments of the population.
Oral squamous cell carcinoma (OSCC) is almost
always preceded by a visible precancerous lesion-dyspla-
sia. As highlighted by the American Dental Association,
“Identifying white and red the spots that show dysplasia
and removing them before they become cancer has
proved to be one of the most effective methods for
reducing the incidence and mortality of cancer” [5].
Malignant transformation of dysplasia, which is quite
unpredictable, occurs over years - during which time
the lesion can be treated, potentially preventing oral
cancer from developing. Oral precancerous lesions may
also occasionally regress if the healthcare professional
motivates the patient to reduce the risk factors including
elimination of carcinogens including tobacco and
alcohol.
Light-based oral cancer screening aids
A number of light-based oral cancer screening aids have
been developed and aimed at assisting in the identifica-
tion of precancerous and cancerous lesions at their ear-
liest stage. (Table 1) Specifically, these aids are intended
to be used as adjuncts to the conventional oral cavity
examination to help visualize lesions. Vizilite Plus with
TBlue system (Zila Pharmaceuticals, Phoenix, Arizona,
U.S.), VELscope (LED Dental, White Rock, British
Columbia, Canada) Microlux/DL (AdDent Inc, Danbury,
Connecticut) and Orascoptic DK (Orascoptic, Middle-
ton, WI) are commercially available light-based systems
that are based upon the assumption that abnormal
metabolic or structural changes have different absor-
bance and reflectance properties.
VELscope is a handheld device that uses visible light in
the 430 nm wavelength in order to cause fluorescent
excitation of certain compounds in the tissues. (Figure
1a) With Vizilite, patients’ first rinse with acetic acid and
then the oral cavity is examined with an illuminated che-
miluminescent light stick. (Figure 1b) Microlux is similar
to Vizilite and requires the patient first rinse with acetic
acid; the oral cavity is then examined with a battery-pow-
ered fiberoptic visible light source instead of a chemilu-
minescent visible light source. Orascoptic DK also
requires an acetic acid rinse and uses a three-in-one
device that employs a battery-powered handheld light
source. Since none of these medical devices is a diagnos-
tic test, the manufacturer of these screening aids do not
make any claim that the device is either sensitive or spe-
cific to the identification of any type of abnormal oral
lesion. Furthermore, as we reported in a prospective
study examining the potential benefits of several of these
lights, the sensitivity of Vizilite was 0% and the sensitivity
of VELscope was also poor-50%. We concluded that the
use of ViziLite or VELscope along with a conventional
screening examination was not beneficial in identifying
dysplasia or cancer and clinicians/and patients could
have a false sense of security after obtaining a negative
ViziLite or VELscope examination result because poten-
tially large numbers of precancerous and cancerous
lesions would be missed by both. Until additional studies
are performed, these screening lights should only be used
to help identify lesions that may have been overlooked
with a conventional oral examination and not for deter-
mining whether a lesion is precancerous or cancerous.
Only a definitive test examining cells or tissue can deter-
mine the biologic behavior of a lesion [6].
Table 1 The various diagnostic modalities for oral cancer
detection.
Visual examination
Excision biopsy and Histopathology
Oral brush biopsy (OralCDx)
Toluidine blue
Light-based detection systems
Chemiluminescence (ViziLite Plus; Microlux/DL, Orascoptic-DK)
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Diagnostic Tests
Cytological Techniques
During the last few decades, oral cytology has resurfaced
as the focus of scientific research. However, in contrast
to the sampling of cells of the uterine cervix, analysis of
surface epithelial cells of the oral cavity and oropharynx
by standard exfoliative cytology has proven unreliable so
far. The shape of the oral cavity makes it impossible to
examine the complete mucosal surface. Without loss of
minimal invasiveness, it was not possible to access the
deeper cell layers of the oral cavity with conventional
exfoliative cytology[7].
Brush Biopsy
During the 1980s, a brush was introduced for cervical
smears in gynecological lesions and was later modified
for oral smears too. (Figure 1c) This technique demon-
strated better cell spreading on objective slides com-
pared with smears obtained by using the conventional
wooden spatula as well as an improvement in the cellu-
lar adequacy of the smears. The importance of oral
brush biopsy was emphasized in a multicenter study
where nearly 5% of clinically benign-appearing oral
mucosal lesions were sampled by using this technique
and later confirmed by using scalpel biopsy to represent
dysplastic epithelial changes or invasive cancer [8].
OralCDx® (OraCDx Laboratories, Inc. Suffern, NY),
the oral brush biopsy with computer assisted analysis, is
a diagnostic test that identifies dysplasia in common
spots that often have no suspicious clinical features.
Unlike exfoliative cytology, the brush biopsy collects
cells from the full thickness of the oral epithelium. The
brush biopsy is a chair-side, easy to perform, painless
test that can be used to evaluate any suspicious lesion
including common small white and red oral lesions to
rule out dysplasia. Since most oral lesions are benign,
most test results are likely to be benign. Approximately
10% of all cases usually turn out to be abnormal. Based
upon the findings, the laboratory provides specific gui-
dance on these abnormal cases sometimes recommend-
ing scalpel biopsy, retesting or observation.
The accuracy of the brush test has been the subject of
many published studies. In every study in which an oral
lesion was simultaneously tested with both a brush
biopsy and scalpel biopsy, this test has been shown to
have a sensitivity and specificity well over 90% [8,9].
These studies demonstrate that the brush biopsy has a
high sensitivity in ruling out the presence of dysplasia
and cancer making it a practical way to evaluate lesions
without an obvious etiology such as infection of trauma.
Discrepancies of brush test and scalpel biopsy results
have been reported anecdotally and have incorrectly
been labeled brush “false negatives.” Unfortunately
these anecdotes been quoted repeatedly in the litera-
ture despite the fact that they have no validity at all.
These discrepant results were all from cases where the
Figure 1 a) Velscope, b) Vizylite with toluidine blue staining, c) Patented brush used for oral brush biopsy test, d) Automated DNA
ploidy.
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scalpel biopsy was performed months after from the
brush biopsy. Within a given oral lesion, dysplasia is
multicentric and unless the 2 biopsy samples happen
to sample the same part of the dysplastic lesion, the
results will be discrepant. Furthermore, the biologic
nature of a lesion may change over time as benign
lesions may become dysplastic and dysplasia may also
regress. Most importantly, the histologic diagnosis of
dysplasia is not easily reproduced amongst oral pathol-
ogists and therefore a discrepant result between brush
biopsy and scalpel biopsy may in fact represent a false
negative or false positive scalpel biopsy result. There-
fore, when comparisons are made between any 2
biopsy techniques (i.e. brush biopsy vs. scalpel biopsy
or scalpel biopsy vs. scalpel biopsy) the only valid stu-
dies are those which compare the results of both biop-
sies performed at the same time and from the same
portion of the suspicious lesion.
To help localize the optimal site for brushing an
abnormality, Gupta et al combined conventional oral
brush biopsy with the application of toluidine blue to
localize suspect mucosal areas [10].
Scalpel biopsy
Until now, tissue sampling by scalpel biopsy and subse-
quent histological examination have been the corner-
stone for diagnosing premalignant and malignant oral
diseases. Unfortunately, scalpel biopsy has many inher-
ent limitations which health care practitioners need to
be aware of. For example, vague histopathological defini-
tions as well as histological misinterpretation resulting
in false negatives and false positives should be kept in
mind while interpreting the results of scalpel biopsies.
An oral biopsy is invasiveand involves both psychologi-
cal implications for the patient as well as possible often
technical difficulties for the health practitioner. When
lesions are extensive, the most representative areas must
be selected to avoid diagnostic errors[11].
Oral biopsy specimens can be affected by a number of
artefacts resulting from crushing, fulguration or incor-
rect fixation and freezing[12]. There is a long standing
controversy regarding selection both of the technique
(incisional versus excisional) and of the surgical instru-
ments used to avoid artefacts; punch biopsy may have
some benefits [13].
Experimental studies have detected an increased fre-
quency of neck metastasis from stage I and stage II
OSCC after incisional biopsy and the presence of
tumour cells have been noticed in the peripheral blood
15 min after incisional biopsies using a conventional
scalpel[14,15]. Consequently, it has been hypothesized
that the use of a laser beam to obtain biopsy material
could minimize seeding of cells but studies are needed
to support this theory[16].
The limitations of comparing 2 biopsy results per-
formed at different time has been highlighted in a study
of 200 patients with leukoplakia, who underwent scalpel
biopsies at different times with an agreement rate
between two scalpel biopsies of only 56%. In addition,
clinicians should be aware of possible under diagnosis
after incisional biopsy-particularly in cases of “hybrid”
forms of OSCC and non-homogeneous lesions, depend-
ing on the site where the biopsy is performed[17,18].
A number of histological characteristics of the primary
tumour, such as the grade of malignancy and depth of
invasion, have been shown to have prognostic value in
terms of tumour recurrence, lymph node involvement,
and cause-specific survival hence, it is important for an
incisional biopsy to be of sufficient size and depth to
include part of the advancing margin of tumour[19].
Ideally, the deep margin should be included, but if this
is not possible (e.g., in large tumours), the peripheral
margin is often sufficiently representative to allow provi-
sional assessment.
Finally, a high inter- and intraobserver variability in
histologically diagnosing dysplasia has been described by
many authors. The difficulty of accurately diagnosing
dysplasia and reproducing those results can have signifi-
cant implications for patients who are provided with
false positive and false negative scalpel biopsy results. As
already highlighted in this review, when two scalpel
biopsies are performed at different times by different
examiners, the agreement rate between them was only
56%[17]. It is evident that even incisional biopsies of
suspicious lesions which have a limited reproducibility
may, at times, result in a more or less aggressive surgical
and/or radio-chemotherapeutic approach[11].
Experimental Screening AIDS and Diagnostic
Tests in Development
Vital staining
Toluidine blue (TB) staining is claimed to be a simple,
inexpensive and sensitive adjunct tool for identifying
early OSCC and high-grade dysplasias [20]. When a 1%
aqueous TB solution is applied to a suspicious lesion for
30 seconds, this acidophilic metachromatic nuclear stain
helps to differentiate areas of carcinoma in situ or inva-
sive carcinoma from normal tissue. Although TB has
been found to be highly sensitive and moderately speci-
fic for malignant lesions, it is far less sensitive for pre-
malignant lesions with false negative rates of up to 58%
reported for identifying mild-to-moderate dysplasia
[10,21].
Toluidine blue has also been demonstrated to help
assess the status of margins around oral cancer at the
time of resection [22]. Although toluidine blue test is
helpful in identifying oral cancers, it should not be
viewed as a substitute for biopsy, and a negative test
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does not preclude the presence of dysplasia or even oral
cancer.
Laser Capture Microdissection
Laser capture microdissection (LCM) has made the
study of cancer biology more precise and has greatly
boosted the efforts in defining the molecular basis of
malignancy [23]. LCM provides an ideal method for the
extraction of cells from specimens in which the exact
morphology of both the captured cells and the sur-
rounding tissue are preserved. When rapid immunohis-
tochemical staining techniques are combined with LCM,
more accurate microdissection of cellular subsets can be
obtained [24]. LCM may be also used to detect the bio-
markers and establish protein fingerprint models for
early detection of OSCC. LCM combined with SELDI-
TOF-MS technology and bioinformatics approaches may
not only facilitate the discovery of better biomarkers but
also provide a useful tool for molecular diagnosis
[25,26].
Dna-Analysis
DNA image cytometry measures ploidy status to deter-
mine the malignant potential of cells. After staining
with Feulgen dye, the cytological samples are compared
with a reference group of cells. A computer-assisted
analysis has been recently designed to identify deviations
of cellular DNA content. Genomic instability contributes
towards cancer development, and abnormal DNA con-
tent may distinguish the dysplastic lesions that might
progress to cancer (Figure 1d) [27]. Several studies con-
firm the usefulness of DNA ploidy analysis as an adjunct
to conventional cytology assessment of cytobrush sam-
ples for detection of oral cancer [27-30]. An increase in
sensitivity and specificity of oral brush biopsy to 100%
has been reported [29,31]. Multimodal cell analysis
(MMCA) and mechanical phenotyping have been used
for early detection of oral malignancies [32,33].
Oral brush samples were examined to detect non-
diploid cells (NDC) combined with morphological and
cytogenetic analysis. It has been suggested that the com-
bined morphological and cytogenetic analysis of cells
collected by a non-invasive brush may enable early
detection of potentially malignant cells [34]. In a study,
Bremmer et al have investigated allelic imbalance in
brushes from 25 patients with leukoplakia and reported
genetic changes in 40% of these patients as compared to
none in controls, yielding a sensitivity of 78% and posi-
tive predictive value of 100% [35].
Saliva-Based Oral Cancer Diagnosis
Saliva testing, a non-invasive alternative to serum test-
ing, may be an effective modality for diagnosis, deter-
mining prognosis of oral cancer and for monitoring
post-therapy status. Saliva, as a diagnostic tool, has
many advantages over serum, aside from the ability of
being collected non-invasively. Saliva may provide a
cost-effective and practical approach for the screening
of large populations. It may be used to measure specific
salivary macromolecules as well as examining proteomic
or genomic targets such as enzymes, cytokines, growth
factors, metalloproteinases, endothelin, telomerase, cyto-
keratins, mRNAs and DNA transcripts [36-38].
The six most studied epithelial serum circulatory
tumor markers in the saliva of carcinoma patients are
Cyfra 21-1, TPS, carcinoembryonic antigen (CEA), SCC,
CA125, and CA19-9. Significant increase (of 400%) in
salivary concentrations of Cyfra 21-1, TPS and CA125
were shown with sensitivity, specificity, and negative and
positive predictive values of 71%, 75%, 71%, and 75%,
respectively. On the other hand CEA, SCC and CA19-9,
did not reach statistical significance[30-41]. CD44, a
multi-structural and multifunctional cell surface trans-
membrane glycoprotein molecule has also been detected
in saliva[42].
Lab-on-a-Chip
Broadly, microfluidics technology -also referred to as
lab-on-a-chip or micro-total-analysis systems (TAS)-is
the adaptation, miniaturization, integration, and automa-
tion of analytical laboratory procedures into a single
device or “chip.” Microfluidics is often regarded as the
chemistry or biotechnology equivalent of the silicon
integrated circuit chip that has revolutionized electro-
nics, computers, and communications. The detection of
oral dysplastic and cancer cells within the chip utilizes
membrane-associated cell proteins that are singularly
expressed on the cell membranes of dysplastic and can-
cer cells as well as their unique gene transcription pro-
files [43].
Microscopy
Spectral cytopathology (SCP) is a recently developed
technique for diagnostic differentiation of disease in
individual exfoliated cells. Papamarkakis et al carried
out SCP by collecting information on each cell’s bio-
chemical composition through infrared micro-spectral
measurement, followed by multivariate data analysis.
Deviations from a cell’s natural composition produced
specific spectral patterns that were exclusive to the
cause of the deviation or disease. These unique spectral
patterns were reproducible and analyzed through multi-
variate statistical methods to detect cells in dysplasia,
neoplasia, or viral infection at the molecular level [44].
Multispectral digital microscope (MDM) has also been
utilized as a tool to improve detection of oral neoplasia.
MDM acquires in-vivo images in different modes i.e.
fluorescence, narrow-band (NB) reflectance, and
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orthogonal polarized reflectance (OPR) to enable evalua-
tion of lesions [45].
Poh et al studied 122 oral mucosal biopsies, 20 surgi-
cal specimens and assessed the fluorescence visualiza-
tion (FV) status, histology and loss of heterozygosity.
They concluded that direct visualization of subclinical
field changes around oral cancers, documenting altera-
tions in fluorescence and direct FV can identify subclini-
cal high-risk fields with cancerous and precancerous
changes in the operating room setting[46].
Spectroscopy
Autofluorescence and chemiluminescencehave been stu-
died as non-invasive in-vivo tools for the detection of
(pre-)malignant tissue alterations. Autofluorescence of
tissues under excitation with light is produced by several
endogenous fluorophores. It was reported that auto-
fluorescence spectroscopy may provide valuable infor-
mation for diagnosis and monitoring the therapeutic
response in oral submucous fibrosisand should be vali-
dated with more studies involving large samples and
longer follow-up[47,48].
The wavelength of absorption is affected by changes in
blood content and oxygenation, which are the signs of
disease due to altered tissue metabolism or neovasculari-
zation. Diffuse reflectance spectroscopy (DRS) has been
studied as a non-invasive in-vivo tool for the detection
of (pre)malignant tissue alterations[49].
In another study, the DRS ratio of oxygenated hemo-
globin bands at 545 and 575 nm was used for grading of
malignancy. A sensitivity of 100% and specificity of 86%
for differentiating dysplasia from hyperplasia, and a sen-
sitivity of 97% and specificity of 86% for discriminating
hyperplasia from normal was obtained [50]. Pavlovaet al
reported that examining oral lesions with optical tools
may result in a loss of fluorescence intensity and may
fail to distinguish benign from precancerous lesions[51].
Tomography
Optical coherence tomography (OCT)is a non-invasive
tomographic imaging modality to detect areas of inflam-
mation, dysplasia and cancer. OCT records subsurface
reflections to build a cross-sectional architectural image
of tissue. Contrast in these images may be enhanced by
utilizing surface plasmon resonant gold nanoparticles. It
was concluded that this multimodal delivery of anti-
body-conjugated Polyethylene glycol linked gold nano-
particles enhances the contrast in in-vivo OCT images
of oral dysplasia in a hamster model [52]. A recent pilot
study in 27 patients confirmed the feasibility of using
OCT to identify architectural changes in malignant cells
but unfortunately, it could not provide a diagnosis or
differentiate between lesions [53].
Conclusions
Early diagnosis of oral cancer is a priority health objec-
tive, in which oral health professionals may play a pivotal
role. Detection should lead to less damage from cancer
therapy and to a better prognosis. There are also a num-
ber of novel techniques that may variously help in the
diagnosis of oral malignancy. Lately, light-based detection
systems have been claimed to improve sensitivity and
specificity, but so far, controlled studies have failed to
justify their application. Brush biopsy and scalpel biopsy
are effective diagnostic tests for evaluating suspicious
oral lesions which may be precancerous or cancerous.
Light based screening aids should only be employed as
an adjunct to the clinical examination for identifying oral
lesions that may have been overlooked with a conven-
tional oral examination and not for determining the bio-
logic nature of a lesion. However, controlled trials in
both high and low risk populations with histologic out-
comes and critical appraisal from the medical community
are required before they can be integrated into practice.
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